Type III

NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society

Retrieved on: 
Tuesday, October 3, 2023
SMA, Spinal muscular atrophy, NMD, EVP, Clinical trial, Myasthenia gravis, EDT, Congress, MG, Patient, Type III, International Congress on Tuberculosis, Pharmaceutical industry

The World Muscle Society Congress is taking place at the Charleston Convention Center in Charleston, South Carolina, US from 3-7 October.

Key Points: 
  • The World Muscle Society Congress is taking place at the Charleston Convention Center in Charleston, South Carolina, US from 3-7 October.
  • Details of NMD Pharma’s poster presentation are below:
    Date and time: Thursday, 5 October from 3:30 pm to 4:30 pm EDT.
  • "The International Congress of the World Muscle Society is one of the most significant scientific gatherings in our field, globally.
  • We eagerly anticipate the opportunity to share data from our clinical trial involving patients with myasthenia gravis," remarked Jorge A. Quiroz, EVP, and Chief Medical Officer at NMD Pharma.

NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society

Retrieved on: 
Tuesday, October 3, 2023
SMA, Spinal muscular atrophy, NMD, EVP, Clinical trial, Myasthenia gravis, EDT, Congress, MG, Patient, Type III, International Congress on Tuberculosis, Pharmaceutical industry

The World Muscle Society Congress is taking place at the Charleston Convention Center in Charleston, South Carolina, US from 3-7 October.

Key Points: 
  • The World Muscle Society Congress is taking place at the Charleston Convention Center in Charleston, South Carolina, US from 3-7 October.
  • Details of NMD Pharma’s poster presentation are below:
    Date and time: Thursday, 5 October from 3:30 pm to 4:30 pm EDT.
  • "The International Congress of the World Muscle Society is one of the most significant scientific gatherings in our field, globally.
  • We eagerly anticipate the opportunity to share data from our clinical trial involving patients with myasthenia gravis," remarked Jorge A. Quiroz, EVP, and Chief Medical Officer at NMD Pharma.

Media Alert: Rambus To Showcase CXL Solutions at SC22

Retrieved on: 
Monday, November 14, 2022
Technology, Hardware, Semiconductor, Data Management, CXL, SC22, SerDes, Conference, Type III, IP, Telecommunications equipment, Rambus

The Conference begins at 8:30 a.m. PT

Key Points: 
  • The Conference begins at 8:30 a.m. PT
    Join Rambus at Supercomputing 2022 in the CXL Consortium Booth #2838 and check out a live demo of Rambus CXL 2.0 interface IP.
  • The demo will show a CXL 2.0 Type 3 endpoint using the Rambus CXL 2.0 controller interoperating with a CXL host.
  • To learn more about Rambus CXL solutions at SC22, visit us at the CXL Consortium Booth #2838.
  • For more details on the latest Rambus chip, high-speed memory, SerDes interface IP and CXL solutions, as well as security IP solutions, visit rambus.com .

INNIO‘s next generation Jenbacher 3F engine offers significantly higher efficiency

Retrieved on: 
Tuesday, October 4, 2022
Environment, Alternative Vehicles, Fuels, Automotive, Automotive Manufacturing, Manufacturing, Alternative Energy, Sustainability, Green Technology, Energy, Hydrogen, 3F, Technology, Jenbacher, Engineering, CEO, Multimedia, Type III, Sustainalytics, THC, Efficiency, Hertz, Renewable energy

INNIO announced today that it has launched its next generation Jenbacher Type 3F engine.

Key Points: 
  • INNIO announced today that it has launched its next generation Jenbacher Type 3F engine.
  • The new and improved Jenbacher Type 3F engine offers customers proven robustness and reliability while delivering up to two percentage points of efficiency boost, the engine lines highest efficiency ever.
  • In addition to delivering efficiency as high as 43.3% when operating on pipeline gas, the Type 3F engine is optimized for reduced total hydrocarbon (THC) emissions, future-proofed fuel flexibility, and enhanced serviceability.
  • View the full release here: https://www.businesswire.com/news/home/20221004005681/en/
    INNIO's next generation Jenbacher Type 3F engine has the line's highest efficiency ever, and its fuel flexibility will allow it to run on hydrogen once the fuel becomes more readily available.

Automotive Fuel Tank Market by Capacity, Material, CNG Tank Type, Propulsion, 2-Wheeler, SCR Technology and Region - Global Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 19, 2021
Automotive, General Automotive, Hydrogen, Tank, SCR, Adoption, Selective catalytic reduction, Pressure, CNG, Industry, CAGR, Motorcycle, Region, USD, Original equipment manufacturer, Aluminium, Type III, ICE, NGV, City, Type 2, Steel, Technology, Gasoline, NOx, Euro, Type 1, LCV, Acceleration, Type 4, CO, Light, PM, Propane

The Type 4 CNG tank is projected to be the fastest-growing segment of the automotive fuel tank market, by CNG Tank Type, during the forecast period.

Key Points: 
  • The Type 4 CNG tank is projected to be the fastest-growing segment of the automotive fuel tank market, by CNG Tank Type, during the forecast period.
  • Asia Pacific to be the largest market for Selective Catalytic Reduction (SCR) Tank segment of the automotive fuel tank market.
  • The Asia Pacific is projected to have the highest share in the global automotive fuel tank market.
  • Increased vehicle production is expected to boost the automotive fuel tank market in the Asia Pacific region during the forecast period.

uniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

Retrieved on: 
Tuesday, November 2, 2021
Safety, Spinocerebellar ataxia, Fabry disease, Phase, Autosome, Haemophilia, Radical behaviorism, Technology, Huntington's disease, Disease, Neurodegeneration, Putamen, CNS, Patient, NASDAQ, Type III, Compte rendu, Data monitoring committee, Review, Brain, Annual report, Forward-looking statement, Risk, Clinical trial, COVID-19, CAG, Chorea, GLOBE, Central nervous system, DSMB, Dementia, Pharmaceutical industry

LEXINGTON, Mass. and AMSTERDAM, Nov. 02, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the positive recommendation by the independent Data Safety Monitoring Board (DSMB) following a review of safety data from the four patient procedures in the higher-dose cohort of the Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease. With the positive recommendation, the final 12 patients in this second cohort are now cleared for enrollment.

Key Points: 
  • With the positive recommendation, the final 12 patients in this second cohort are now cleared for enrollment.
  • In the study to date, eight patients have been treated with AMT-130, and six patients have received imitation surgery.
  • The European, open-label Phase Ib/II study of AMT-130 will enroll 15 patients with early manifest Huntingtons disease across two dose cohorts.
  • Phase I/II or the European open-label Phase Ib/II clinical trials, , and whether we share initial imaging and biomarker data towards the end of the year or ever.

uniQure to Participate in Upcoming Industry Conferences in November

Retrieved on: 
Monday, November 1, 2021
Spinocerebellar ataxia, Fabry disease, Haemophilia, Technology, Temporal lobe, Huntington's disease, CNS, HRU, Patient, NASDAQ, Type III, Investor, Virtual, Mirna, Doctor of Philosophy, Conference, Temporal lobe epilepsy, Q&A, GLOBE, Central nervous system, Liver, ALS, Animal, Pharmaceutical industry

Stifel 2021 Virtual Healthcare Conference, November 15 - 17, 2021

Key Points: 
  • Stifel 2021 Virtual Healthcare Conference, November 15 - 17, 2021
    Members of uniQures management team, including Matt Kapusta , chief executive officer, will participate in virtual one-on-one investor meetings on Wednesday, November 17th.
  • A fireside chat with Mr. Kapusta will take place the same day from 10:40 to 11:10 a.m.
  • The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website.
  • uniQure is delivering on the promise of gene therapy single treatments with potentially curative results.

uniQure Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Monday, October 25, 2021
Safety, Efficiency, Disease, BLA, GRIK2, ESGCT, Spinal cord, Cell, Marketing, Hippocampus, IPSC, Clinical trial, COVID-19, Temporal lobe epilepsy, Gene, Program, Acquisition, D, GLOBE, Locomotion, Liver, Spinocerebellar ataxia, Phase, Research, Neuron, SVB Leerink, Type III, Food, Mirna, Data monitoring committee, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Brain, Annual report, Risk, Company, Hercules, Epilepsy, DSMB, Industry, CSL Behring, TLE, CSL, Sale, Heart, ALS, AAV, C9orf72, Fabry disease, Annual general meeting, Haemophilia, Technology, Huntington's disease, Patient, NASDAQ, FDA, Conference, Kidney, FIX, European Society of Gene and Cell Therapy, Forward-looking statement, Development, Animal, Pharmaceutical industry, Medical device, Vaccine, Cryptocurrency, Reinsurance

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Oct. 25, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the third quarter of 2021 and highlighted recent progress across its business.

Key Points: 
  • and AMSTERDAM, The Netherlands, Oct. 25, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the third quarter of 2021 and highlighted recent progress across its business.
  • Along with our global partner, CSL Behring, the Company expects to announce top-line data from the HOPE-B trial in the late fourth quarter of 2021.
  • As part of these efforts, the Company anticipates completing the validation of its commercial manufacturing process before year-end 2021.
  • In July 2021, the Company closed the acquisition of Corlieve Therapeutics, a pre-clinical gene therapy company based in France.

uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors

Retrieved on: 
Thursday, October 21, 2021
Spinocerebellar ataxia, Fabry disease, Business operations, Biotechnology, Haemophilia, Baxter, Nephrology, Dow Corning, Neurology, Baxter International, Technology, Huntington's disease, Industry, Bachelor of Arts, Shire (pharmaceutical company), Hematology, Alexion Pharmaceuticals, Regenerative medicine, CNS, ALS, BLA, Patient, Marketing, NASDAQ, Type III, Ernst & Young, Senior, Company, Touche, Board, Alma College, Temporal lobe epilepsy, Program, ARM, Acquisition, Deloitte, GLOBE, Central nervous system, Liver, Director, Board of directors, Pharmaceutical industry, Management

and AMSTERDAM, Oct. 21, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Rachelle Jacques to its Board of Directors.

Key Points: 
  • and AMSTERDAM, Oct. 21, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Rachelle Jacques to its Board of Directors.
  • "It is with great pleasure that we welcome Rachelle to the uniQure board, stated Matthew Kapusta , chief executive officer of uniQure.
  • I am pleased with this opportunity to join the uniQure Board of Directors at such an exciting time for the Company, stated Ms. Jacques.
  • Since April 2019, Ms. Jacques has served on the Board of Directors of Corbus Pharmaceuticals (NASDAQ: CRBP), and from April 2020 to February 2021, she served on the Board of Directors of Viela Bio.

uniQure Announces Presentations at the Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)

Retrieved on: 
Tuesday, October 19, 2021
ALS, AAV, Nociception, IND, Annual general meeting, GLA, Liver, European Society of Gene and Cell Therapy, NASDAQ, CNS, Neuron, GB3, Technology, Gene, COVID-19, Kidney, Cell, Fabry disease, Haemophilia, Spinal cord, Time, TLE, Type III, CEST, Disease, Epilepsy, Central nervous system, IPSC, Program, Research, C9orf72, Spinocerebellar ataxia, Risk, GLOBE, Brain, Patient, Huntington's disease, Temporal lobe epilepsy, ESGCT, Forward-looking statement, Efficiency, Heart, Phenotype, Locomotion, GRIK2, Pharmaceutical industry, Vaccine

and AMSTERDAM, The Netherlands, Oct. 19, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that four data presentations, including one oral presentation, will be delivered at the European Society of Gene and Cell Therapy (ESGCT) 28th Annual Meeting taking place virtually today through October 22, 2021.

Key Points: 
  • and AMSTERDAM, The Netherlands, Oct. 19, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that four data presentations, including one oral presentation, will be delivered at the European Society of Gene and Cell Therapy (ESGCT) 28th Annual Meeting taking place virtually today through October 22, 2021.
  • AMT-191 is a one-time administered AAV5 gene therapy incorporating an -galactosidase A (GLA) transgene.
  • Moreover, pre-clinical studies in non-human primates with AMT-191 demonstrated robust and sustained increases in GLA activity in multiple organs.
  • uniQure is delivering on the promise of gene therapy single treatments with potentially curative results.